RxDoctor Payments DataLook up a doctor →

Parag Patel, MD

Interventional Cardiology · Safety Harbor, FLNPI 1821241324

Payments from drug & device makers

$950,096in general payments, 2019–2025

Across 455 payments — averaging $2088.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$821K
  • M.a. Med Alliance S.A.$46K
  • Abbott$22K
  • Angiodynamics, Inc.$22K
  • Bard Peripheral Vascular, Inc.$14K
  • Boston Scientific$8K
  • plus $17K from 39 others
$26in research payments, 2019–2025

Across 1 payment — averaging $26.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$26

What the payments were for

  • Consulting fees$4501%
  • Speaking & faculty fees$14,93828%
  • Travel & lodging$3,5407%
  • Food & beverage$13,22224%
  • Education$120%
  • Gifts$400%
  • Other$21,91740%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$950,096 in reported general payments places this provider in the 95th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$668,271
Medicare patients
1,189
Services billed
4,421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban383$337,360
XareltoRivaroxaban194$209,238
BrilintaTicagrelor181$116,589
JardianceEmpagliflozin72$76,116
EntrestoSacubitril/Valsartan70$59,724
Repatha SureclickEvolocumab63$57,586
MultaqDronedarone Hcl12$22,901
Repatha SyringeEvolocumab30$17,226
FarxigaDapagliflozin Propanediol21$16,301
Ranolazine ErRanolazine86$11,352
Dabigatran EtexilateDabigatran Etexilate Mesylate46$9,060
ClopidogrelClopidogrel Bisulfate879$8,894
Metoprolol Succinate586$8,715
Atorvastatin Calcium575$6,199
Losartan Potassium328$3,923

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$156$337,360383 claims
Johnson & JohnsonXarelto$49$209,238194 claims
AstraZenecaBrilinta, Farxiga$655$132,890202 claims
NovartisEntresto$182$59,72470 claims
Sanofi-aventis U.S. LLCMultaq$42$22,90112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Safety Harbor

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →